{"id":389227,"date":"2020-11-30T02:16:24","date_gmt":"2020-11-30T07:16:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=389227"},"modified":"2020-11-30T02:16:24","modified_gmt":"2020-11-30T07:16:24","slug":"number-of-shares-and-votes-in-oncopeptides-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/number-of-shares-and-votes-in-oncopeptides-4\/","title":{"rendered":"Number of shares and votes in Oncopeptides"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n STOCKHOLM<\/span>, Nov. 30, 2020<\/span> \/PRNewswire\/ — Oncopeptides AB (Nasdaq Stockholm, ONCO), <\/b>a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, \u00a0today announces that the number of shares and votes in Oncopeptides has changed due to the exercise of warrants under the company’s incentive program.<\/p>\n

Through the exercise of warrants under the company’s incentive program, the number of outstanding shares and votes has increased by 169,032 from 67,770,683 to 67,939,715. The share capital has increased by approximately SEK 18,781<\/span> from SEK 7,530,076<\/span> to SEK 7,548,857<\/span>.<\/p>\n

\n For further information, please contact:<\/b>
\n
Anders Martin-L\u00f6f, CFO of Oncopeptides
E-mail: anders.martin-lof@oncopeptides.com<\/a>\u00a0
Telephone: +46 (0) 70\u00a0683 79 77<\/p>\n

Rein Piir, Head of Investor Relations at Oncopeptides
E-mail: rein.piir@oncopeptides.com<\/a>
Cell phone: +46 70 853 72 92<\/p>\n

The information in the press release is information that Oncopeptides is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons above, on November 30, 2020<\/span> at 08.00 (CET).<\/p>\n

\n About Oncopeptides
<\/b>
\n
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Melflufen (INN melphalan flufenamide) is in development as a new treatment for the hematological malignancy multiple myeloma and is currently being tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Based on the results from the HORIZON study Oncopeptides has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen in combination with dexamethasone for treatment of adult patients with triple-class refractory multiple myeloma. Oncopeptides’ global Headquarters is in Stockholm, Sweden<\/span> and the U.S. Headquarters is situated in Boston, Mass.<\/span> The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com<\/a>.<\/p>\n

This information was brought to you by Cision http:\/\/news.cision.com<\/a><\/p>\n

\n https:\/\/news.cision.com\/oncopeptides-ab\/r\/number-of-shares-and-votes-in-oncopeptides,c3244622<\/a>\n <\/p>\n

The following files are available for download:<\/p>\n

\n\n\n
\n

\n
\n https:\/\/mb.cision.com\/Main\/15404\/3244622\/1340660.pdf<\/a>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Press release – Number of shares and votes in Oncopeptides<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\u00a0<\/p>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/number-of-shares-and-votes-in-oncopeptides-301181437.html<\/a><\/p>\n

SOURCE Oncopeptides AB<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire STOCKHOLM, Nov. 30, 2020 \/PRNewswire\/ — Oncopeptides AB (Nasdaq Stockholm, ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, \u00a0today announces that the number of shares and votes in Oncopeptides has changed due to the exercise of warrants under the company’s incentive program. Through the exercise of warrants under the company’s incentive program, the number of outstanding shares and votes has increased by 169,032 from 67,770,683 to 67,939,715. The share capital has increased by approximately SEK 18,781 from SEK 7,530,076 to SEK 7,548,857. For further information, please contact: Anders Martin-L\u00f6f, CFO of OncopeptidesE-mail: anders.martin-lof@oncopeptides.com\u00a0 Telephone: +46 (0) 70\u00a0683 79 77 Rein Piir, Head of Investor Relations at OncopeptidesE-mail: rein.piir@oncopeptides.comCell phone: +46 70 … <\/p>\n

Continue reading “Number of shares and votes in Oncopeptides”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-389227","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNumber of shares and votes in Oncopeptides - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/number-of-shares-and-votes-in-oncopeptides-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Number of shares and votes in Oncopeptides - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire STOCKHOLM, Nov. 30, 2020 \/PRNewswire\/ — Oncopeptides AB (Nasdaq Stockholm, ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, \u00a0today announces that the number of shares and votes in Oncopeptides has changed due to the exercise of warrants under the company’s incentive program. Through the exercise of warrants under the company’s incentive program, the number of outstanding shares and votes has increased by 169,032 from 67,770,683 to 67,939,715. The share capital has increased by approximately SEK 18,781 from SEK 7,530,076 to SEK 7,548,857. For further information, please contact: Anders Martin-L\u00f6f, CFO of OncopeptidesE-mail: anders.martin-lof@oncopeptides.com\u00a0 Telephone: +46 (0) 70\u00a0683 79 77 Rein Piir, Head of Investor Relations at OncopeptidesE-mail: rein.piir@oncopeptides.comCell phone: +46 70 … Continue reading "Number of shares and votes in Oncopeptides"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/number-of-shares-and-votes-in-oncopeptides-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-30T07:16:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO05917&sd=2020-11-30\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/number-of-shares-and-votes-in-oncopeptides-4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/number-of-shares-and-votes-in-oncopeptides-4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Number of shares and votes in Oncopeptides\",\"datePublished\":\"2020-11-30T07:16:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/number-of-shares-and-votes-in-oncopeptides-4\\\/\"},\"wordCount\":389,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/number-of-shares-and-votes-in-oncopeptides-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO05917&sd=2020-11-30\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/number-of-shares-and-votes-in-oncopeptides-4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/number-of-shares-and-votes-in-oncopeptides-4\\\/\",\"name\":\"Number of shares and votes in Oncopeptides - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/number-of-shares-and-votes-in-oncopeptides-4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/number-of-shares-and-votes-in-oncopeptides-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO05917&sd=2020-11-30\",\"datePublished\":\"2020-11-30T07:16:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/number-of-shares-and-votes-in-oncopeptides-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/number-of-shares-and-votes-in-oncopeptides-4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/number-of-shares-and-votes-in-oncopeptides-4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO05917&sd=2020-11-30\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO05917&sd=2020-11-30\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/number-of-shares-and-votes-in-oncopeptides-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Number of shares and votes in Oncopeptides\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Number of shares and votes in Oncopeptides - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/number-of-shares-and-votes-in-oncopeptides-4\/","og_locale":"en_US","og_type":"article","og_title":"Number of shares and votes in Oncopeptides - Market Newsdesk","og_description":"PR Newswire STOCKHOLM, Nov. 30, 2020 \/PRNewswire\/ — Oncopeptides AB (Nasdaq Stockholm, ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, \u00a0today announces that the number of shares and votes in Oncopeptides has changed due to the exercise of warrants under the company’s incentive program. Through the exercise of warrants under the company’s incentive program, the number of outstanding shares and votes has increased by 169,032 from 67,770,683 to 67,939,715. The share capital has increased by approximately SEK 18,781 from SEK 7,530,076 to SEK 7,548,857. For further information, please contact: Anders Martin-L\u00f6f, CFO of OncopeptidesE-mail: anders.martin-lof@oncopeptides.com\u00a0 Telephone: +46 (0) 70\u00a0683 79 77 Rein Piir, Head of Investor Relations at OncopeptidesE-mail: rein.piir@oncopeptides.comCell phone: +46 70 … Continue reading \"Number of shares and votes in Oncopeptides\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/number-of-shares-and-votes-in-oncopeptides-4\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-30T07:16:24+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO05917&sd=2020-11-30","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/number-of-shares-and-votes-in-oncopeptides-4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/number-of-shares-and-votes-in-oncopeptides-4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Number of shares and votes in Oncopeptides","datePublished":"2020-11-30T07:16:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/number-of-shares-and-votes-in-oncopeptides-4\/"},"wordCount":389,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/number-of-shares-and-votes-in-oncopeptides-4\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO05917&sd=2020-11-30","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/number-of-shares-and-votes-in-oncopeptides-4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/number-of-shares-and-votes-in-oncopeptides-4\/","name":"Number of shares and votes in Oncopeptides - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/number-of-shares-and-votes-in-oncopeptides-4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/number-of-shares-and-votes-in-oncopeptides-4\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO05917&sd=2020-11-30","datePublished":"2020-11-30T07:16:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/number-of-shares-and-votes-in-oncopeptides-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/number-of-shares-and-votes-in-oncopeptides-4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/number-of-shares-and-votes-in-oncopeptides-4\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO05917&sd=2020-11-30","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO05917&sd=2020-11-30"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/number-of-shares-and-votes-in-oncopeptides-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Number of shares and votes in Oncopeptides"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=389227"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389227\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=389227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=389227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=389227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}